{
  "links": "https://www.ycombinator.com/companies/menten-ai",
  "name": "Menten AI",
  "headline": "Menten AI designs peptide and protein therapeutics using quantumâ¦",
  "batch": "W20",
  "description": "Menten AI designs protein drugs and enzymes using quantum computing and machine learning. Their technology leapfrogs current computational methods making it possible to design previously intractable proteins. The team created the first protein design algorithm for current and near-term quantum computers and created the worldâs first protein designed on a quantum computer. They are now working on 3 new proteins, including a peptide to prevent the spread of viruses like Covid-19. They have 2 paid pilot projects with multinational chemical companies and 4 LOIâs with pharma and biotech companies.",
  "activity_status": "Active",
  "website": "http://menten.ai",
  "founded_date": null,
  "team_size": 2.0,
  "location": "San Francisco",
  "group_partner": null,
  "group_partner_yc": null,
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:ai-powered-drug-discovery; industry:quantum-computing; location:san-francisco-bay-area",
  "founders": [
    {
      "name": "Tamas Gorbe, Founder",
      "description": "TechBio startup founder with hands-on operational and finance experience. Working at the intersection of chemistry, biology, and computer science.\nPassionate about investing and value creation in the Life Science ecosystem.\nOutside of work, I enjoy several different sports activities, such as scuba diving, surfing, MTB, wakeboarding, and have 10 years of triathlon experience.",
      "linkedin": "https://www.linkedin.com/in/tamasgorbe/"
    },
    {
      "name": "Hans Melo, Founder",
      "description": null,
      "linkedin": "https://www.linkedin.com/in/hansmelo/"
    }
  ],
  "status": true,
  "markdown": "raw_markdown=\"[![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74069879b23ce12352a3_mentenai_logo-02.png)](http://menten.ai/</>)\\n[](http://menten.ai/<#>)\\n[about](http://menten.ai/</>)[team](http://menten.ai/</team>)[publications](http://menten.ai/</publications>)[newsroom](http://menten.ai/</news>)[Careers](http://menten.ai/</careers>)[Partner with us](http://menten.ai/</contact>)\\n# Generative AI forPeptide Drug Design\\nBuilding the world's most advanced **generative AI** platform for peptide therapeutics.\\n[Learn more](http://menten.ai/<#WhatWeDo>)[Careers](http://menten.ai/</careers>)\\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/63875495f832b4eff1845dc6_peptide%20as%20drugs.png)\\n## How we do it\\n**Physics-Based Design meets Generative Machine Learning \\u200d** The Menten AI platform overcomes historical limitations in drug design by developing machine learning-based methods that leverage first principle physics-based methods for molecular modeling. Existing design methodologies are limited by small datasets, computationally expensive sampling methods, and inaccurate accuracy simulations, ultimately precluding the design of potent drug molecules. By contrast, Menten AI’s platform is able to create its own data from first principles and apply machine learning to guide the design and optimization of novel peptides. The advantage of this approach is that we can create novel drug-like chemical matter not seen before efficiently and with high accuracy.The Menten platform achieves desirable drug properties directly from _in silico_ design including nM potency, high plasma stability, as well as cell-permeability and oral bioavailability. \\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/6474d0c52033195c9471c11a_D3771EDE-5042-4558-9CA0-28A23A481DF0.png)![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/6387539bd2bf2583af30622e_menten%20funnel.png)\\n## About Us\\nBacked by top-tier VCs including Uncork Capital, Khosla Ventures, Social Impact Capital, and Y-Combinator, Menten AI is enabling a **new type of drug for currently** **undruggable targets** using machine learning. The Menten AI platform designs**peptide macrocycles** in a larger chemical space (1050 compared to 109 for high throughput platforms) and in record time (8 weeks vs 1-2 year in industry). This equates to **10,000x greater sampling power in ⅙ the time with >50% in vitro hit success compared to ~9% in industry**. We have validated the platform by creating multiple hit molecules across a variety of drug targets including an anti-viral peptide forCovid-19. **Drug Design Platform** Menten AI’s platform delivers drug-like **hit molecules in a single round** of design in 8 weeks. The team’s first focus is peptide macrocycles. Peptides are the ideal drug modality for undruggable and hard-to-drug targets which remain beyond the reach of small molecules and biologics. **Validation** Menten AI’s platform has been validated across the preclinical discovery pipeline from _in silico_ , to _in vitro_ and _in vivo_ efficacy with several peptides having already shown drug-like DMPK properties and in vivo efficacy.\\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/6273ffb5513a95561fe610e7_peptide%20icon.png)\\n### **Peptide Macrocycles**\\nDe novo designed peptide drugs offer the advantages of both small molecules and large biologics in one molecule.\\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/6273ffb4f451fc6b7e798740_peptide%20drug%20conjugate.png)\\n### **Peptide Drug Conjugates**\\nBi-functional molecules for the recruitment of cytotoxic immune effectors with a focus on immune-oncology applications. \\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb06797a0b0a348b_pic4.jpg)\\n## our investors\\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb0679e75d0a3469_uncork_logo.png)![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb0679551f0a347c_y_combinator_logo.png)![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb06791d910a3462_khosla_ventures_logo.png)![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb0679ffa10a3484_sic_logo.png)![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb0679731a0a346b_FoundersX%20logo_transparent.png)![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb0679df7f0a3478_creative-destruction-lab.png)\\n## let’s talk\\nSend us an email to learn about our partnership and career opportunities or for additional questions.\\n[contact us](http://menten.ai/</contact>)\\n[![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef7507fb06792e1f0a35f7_mentenai_logo-03.svg)](http://menten.ai/</>)\\n© Copyright 2021. Menten AI. All rights reserved!\\nBranding, webdesign & developement: [.gregzi](http://menten.ai/<http:/www.gregzi.com>)\\n[![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef7507fb067976c10a35f9_social--linkedin%20icon%201.svg)](http://menten.ai/<https:/www.linkedin.com/company/menten-ai/>)[![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef7507fb067961f80a35fa_social--twitter%20icon%201.svg)](http://menten.ai/<https:/twitter.com/menten_ai>)[![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef7507fb067935cf0a35fc_social--instagram%20icon%201.svg)](http://menten.ai/<https:/www.instagram.com/menten.ai/?hl=en>)\\nFollow for updates!\\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef7507fb06797f800a35f8_mail%201.svg)info@menten.ai\\n\" markdown_with_citations=\"![⟨1⟩](http://menten.ai/</>)\\n[](http://menten.ai/<#>)\\nabout⟨2⟩team⟨3⟩publications⟨4⟩newsroom⟨5⟩Careers⟨6⟩Partner with us⟨7⟩\\n# Generative AI forPeptide Drug Design\\nBuilding the world's most advanced **generative AI** platform for peptide therapeutics.\\nLearn more⟨8⟩Careers⟨6⟩\\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/63875495f832b4eff1845dc6_peptide%20as%20drugs.png)\\n## How we do it\\n**Physics-Based Design meets Generative Machine Learning \\u200d** The Menten AI platform overcomes historical limitations in drug design by developing machine learning-based methods that leverage first principle physics-based methods for molecular modeling. Existing design methodologies are limited by small datasets, computationally expensive sampling methods, and inaccurate accuracy simulations, ultimately precluding the design of potent drug molecules. By contrast, Menten AI’s platform is able to create its own data from first principles and apply machine learning to guide the design and optimization of novel peptides. The advantage of this approach is that we can create novel drug-like chemical matter not seen before efficiently and with high accuracy.The Menten platform achieves desirable drug properties directly from _in silico_ design including nM potency, high plasma stability, as well as cell-permeability and oral bioavailability. \\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/6474d0c52033195c9471c11a_D3771EDE-5042-4558-9CA0-28A23A481DF0.png)![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/6387539bd2bf2583af30622e_menten%20funnel.png)\\n## About Us\\nBacked by top-tier VCs including Uncork Capital, Khosla Ventures, Social Impact Capital, and Y-Combinator, Menten AI is enabling a **new type of drug for currently** **undruggable targets** using machine learning. The Menten AI platform designs**peptide macrocycles** in a larger chemical space (1050 compared to 109 for high throughput platforms) and in record time (8 weeks vs 1-2 year in industry). This equates to **10,000x greater sampling power in ⅙ the time with >50% in vitro hit success compared to ~9% in industry**. We have validated the platform by creating multiple hit molecules across a variety of drug targets including an anti-viral peptide forCovid-19. **Drug Design Platform** Menten AI’s platform delivers drug-like **hit molecules in a single round** of design in 8 weeks. The team’s first focus is peptide macrocycles. Peptides are the ideal drug modality for undruggable and hard-to-drug targets which remain beyond the reach of small molecules and biologics. **Validation** Menten AI’s platform has been validated across the preclinical discovery pipeline from _in silico_ , to _in vitro_ and _in vivo_ efficacy with several peptides having already shown drug-like DMPK properties and in vivo efficacy.\\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/6273ffb5513a95561fe610e7_peptide%20icon.png)\\n### **Peptide Macrocycles**\\nDe novo designed peptide drugs offer the advantages of both small molecules and large biologics in one molecule.\\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/6273ffb4f451fc6b7e798740_peptide%20drug%20conjugate.png)\\n### **Peptide Drug Conjugates**\\nBi-functional molecules for the recruitment of cytotoxic immune effectors with a focus on immune-oncology applications. \\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb06797a0b0a348b_pic4.jpg)\\n## our investors\\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb0679e75d0a3469_uncork_logo.png)![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb0679551f0a347c_y_combinator_logo.png)![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb06791d910a3462_khosla_ventures_logo.png)![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb0679ffa10a3484_sic_logo.png)![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb0679731a0a346b_FoundersX%20logo_transparent.png)![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74e0fb0679df7f0a3478_creative-destruction-lab.png)\\n## let’s talk\\nSend us an email to learn about our partnership and career opportunities or for additional questions.\\ncontact us⟨7⟩\\n![⟨9⟩](http://menten.ai/</>)\\n© Copyright 2021. Menten AI. All rights reserved!\\nBranding, webdesign & developement: .gregzi⟨10⟩\\n![⟨11⟩](http://menten.ai/<https:/www.linkedin.com/company/menten-ai/>)![⟨12⟩](http://menten.ai/<https:/twitter.com/menten_ai>)![⟨13⟩](http://menten.ai/<https:/www.instagram.com/menten.ai/?hl=en>)\\nFollow for updates!\\n![](https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef7507fb06797f800a35f8_mail%201.svg)info@menten.ai\\n\" references_markdown='\\n\\n## References\\n\\n⟨1⟩ https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef74069879b23ce12352a3_mentenai_logo-02.png: ![\\n⟨2⟩ http://menten.ai/</>: about\\n⟨3⟩ http://menten.ai/</team>: team\\n⟨4⟩ http://menten.ai/</publications>: publications\\n⟨5⟩ http://menten.ai/</news>: newsroom\\n⟨6⟩ http://menten.ai/</careers>: Careers\\n⟨7⟩ http://menten.ai/</contact>: Partner with us\\n⟨8⟩ http://menten.ai/<#WhatWeDo>: Learn more\\n⟨9⟩ https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef7507fb06792e1f0a35f7_mentenai_logo-03.svg: ![\\n⟨10⟩ http://menten.ai/<http:/www.gregzi.com>: .gregzi\\n⟨11⟩ https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef7507fb067976c10a35f9_social--linkedin%20icon%201.svg: ![\\n⟨12⟩ https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef7507fb067961f80a35fa_social--twitter%20icon%201.svg: ![\\n⟨13⟩ https://cdn.prod.website-files.com/5ebfaec6b7798ed07f5dcf3a/5eef7507fb067935cf0a35fc_social--instagram%20icon%201.svg: ![\\n' fit_markdown='' fit_html=''",
  "generated_description": "### Menten AI: Pioneering Peptide and Protein Therapeutics with Quantum Computing\n\n**Overview**  \nMenten AI is a groundbreaking company based in San Francisco, forged in the fires of Y Combinator's W20 batch. The company specializes in designing peptide and protein therapeutics by leveraging the power of quantum computing and machine learning. Founded in an era where traditional computational approaches face significant hurdles, Menten AI is charting a new path in drug discovery.\n\n**Mission**  \nThe driving mission of Menten AI is to create powerful therapeutics that can tackle \"undruggable\" targets—essentially, diseases and conditions for which current treatments do not exist or fail to yield effective results.\n\n**Innovative Technology**  \nWhat sets Menten AI apart is its innovative approach that combines physics-based design with generative machine learning. This unique methodology allows them to overcome historical limitations prevalent in drug design, such as small datasets and inefficient sampling methods. In practice, this means they can produce viable drug-like candidates in record time: typically within 8 weeks, compared to the industry standard of 1 to 2 years.\n\nKey milestones for Menten AI include:\n- Development of the first protein design algorithm specifically for current and near-term quantum computers.\n- Creating the world's first protein designed on a quantum computer.\n- Ongoing projects to design three new proteins, with one aimed at preventing the spread of viruses like Covid-19.\n\n**Current Partnerships and Projects**  \nMenten AI is not just an abstract idea; they are currently engaged in tangible projects:\n- They’ve executed two paid pilot projects with multinational chemical companies.\n- They also have four letters of intent (LOIs) from various pharmaceutical and biotech firms eager to collaborate.\n\n**The Future of Drug Design**  \nTheir approach offers a staggering increase in efficiency, boasting a 10,000x greater sampling power with a hit success rate in vitro of over 50%, far surpassing the industry average of around 9%. This method not only promises rapid drug candidate generation but has already validated efficacy at various stages of the preclinical discovery pipeline.\n\nBacked by esteemed investors including Khosla Ventures, Uncork Capital, and Social Impact Capital, Menten AI is not just creating drugs; they are crafting a new paradigm for drug discovery.\n\n**Wrap-Up**  \nMenten AI is poised to revolutionize the biopharmaceutical landscape. By harnessing the capabilities of generative AI and quantum computing, they are pushing the boundaries of what is possible in drug discovery, offering hope against some of the most challenging health threats today.\n\nFor more details, you can visit their website at [menten.ai](http://menten.ai)."
}